CN1769299A - Novel fusion protein production and uses - Google Patents
Novel fusion protein production and uses Download PDFInfo
- Publication number
- CN1769299A CN1769299A CN 200510085497 CN200510085497A CN1769299A CN 1769299 A CN1769299 A CN 1769299A CN 200510085497 CN200510085497 CN 200510085497 CN 200510085497 A CN200510085497 A CN 200510085497A CN 1769299 A CN1769299 A CN 1769299A
- Authority
- CN
- China
- Prior art keywords
- fusion rotein
- afgf
- sequence
- ser
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract description 8
- 102000037865 fusion proteins Human genes 0.000 title abstract description 7
- 230000014616 translation Effects 0.000 title 1
- 230000004927 fusion Effects 0.000 claims abstract description 55
- 108060008226 thioredoxin Proteins 0.000 claims abstract description 8
- 229940094937 thioredoxin Drugs 0.000 claims abstract description 6
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 27
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 11
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 238000013016 damping Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 229920002684 Sepharose Polymers 0.000 claims description 5
- 238000010353 genetic engineering Methods 0.000 claims description 5
- 210000003000 inclusion body Anatomy 0.000 claims description 5
- 238000004153 renaturation Methods 0.000 claims description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 102100036407 Thioredoxin Human genes 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000013467 fragmentation Methods 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 3
- 101710135378 pH 6 antigen Proteins 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 238000003113 dilution method Methods 0.000 claims description 2
- 238000000703 high-speed centrifugation Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 9
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 abstract description 5
- 102000002933 Thioredoxin Human genes 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000029663 wound healing Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 26
- 206010052428 Wound Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 13
- 239000007983 Tris buffer Substances 0.000 description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000035617 depilation Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 101100120045 Bos taurus FGF1 gene Proteins 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102220023257 rs387907546 Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 238000005267 amalgamation Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 244000179560 Prunella vulgaris Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102220023258 rs387907548 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940040591 biotech drug Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 102220369446 c.1274G>A Human genes 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 102220023256 rs387907547 Human genes 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000009724 venous congestion Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a production method and use of a novel fusion protein, in particular a human acidic fibroblast growth factor variant fusion protein and its preparing process, wherein the fusion protein is the fusion of human acidic fibroblast growth factor variant with thioredoxin, the fusion protein can be used for the treatment of wound healing.
Description
Technical field:
The present invention relates to a kind of biotech drug, particularly relate to human acid fibroblast growth factor variant fusion rotein and preparation method thereof, described fusion rotein is the syzygy of human acid fibroblast growth factor variant and Trx, and this fusion rotein can be applicable to fields such as therapeutic wound healing.
Background technology:
Human acid fibroblast growth factor (Human acidic fibroblast growth factor is called for short: aFGF or haFGF) is one of member of human inner cell's growth factor family.Can promote the mitotic division and the differentiation of various kinds of cell such as epithelial cell, neurocyte.
AFGF helps vascularization and injury repairing, has the potential clinical value aspect treatment chronic soft tissue ulcer and venous congestion, the glycosuria germ leg ulcer of foot; Jefferson medical college and Merck Sharp ﹠amp; The Dohme research laboratory has finished aFGF jointly and has promoted the research work that blood vessel is repaired, and confirms that aFGF is preventing postangioplasty because the angiostenosis that vascellum tunica interna incrassation causes is effective in cure; AFGF has neurotrophic effect, and in the retinal ganglial cells damage, aFGF has special cytothesis effect.U.S. Georgetown university research personnel sum up and think aFGF in the treatment of central nervous system injury, have the function of the injured neurons kept, stimulation revascularization; Spain Ramony Cajal medical college has confirmed that aFGF has provide protection to brain damage, can prevent the neurone degraded, and can significantly improve the survival rate of the damaged animal of spinal cord; The German Research personnel find that aFGF plays an important role for the healing of myocardium micronecrosis; The experiment of Japan Okayama Univ. shows that aFGF can induce HGF synthetic in a large number in vivo, and the latter plays important physiological function for liver regeneration.
But the aFGF original shape is stable poor, in clinical and practical application many restrictions is arranged.Sophisticated aFGF albumen is made up of 140 amino acid, and 6 amino acid of its N end disappearance still have activity, and the ED50 value of BALB/c 3T3 cell proliferation is about 40pg/ml, also has the 10 μ g aFGF of report to be enough to activate vascular endothelial cell.AFGF albumen iso-electric point is 5.8, molecular weight 16Kd (10).3 halfcystines (Cys16, Cys83, Cys117) are arranged in the primary structure of aFGF molecule, but do not have interchain disulfide bond, in aqueous environment, show as single chain protein.Researchs such as Thomas replace Cys16, Cys83, Cys117 with Serine respectively individually or simultaneously, promptly form S16, S16.S83, S16.S117, S83, S83.S117, S117, mutant such as S16.S83.S117 found that the biologic activity of these aFGF mutant obviously reduces the heparin dependency.
Intestinal bacteria thioredoxin (Tioredoxin), the reduction of catalysis disulfide linkage and exchange, and the oxidation of free thiol group.This albumen is expressed in colibacillus periplasm, is essential for effective formation of disulfide linkage in the colibacillus periplasm.Promote proteinic refolding external, the present invention finds unexpectedly that with human acid fibroblast growth and intestinal bacteria thioredoxin amalgamation and expression its stability and biologic activity obviously improve.
The present invention adopts gene engineering method, and efficiently expressing recombinant human aFGF variant fusion rotein engineering strain is produced a large amount of reorganization aFGF variant fusion roteins, and worked out liquid and the freeze-dried preparation that is suitable for clinical therapeutic wound healing application in intestinal bacteria.
Summary of the invention:
The invention provides a kind of human acid fibroblast growth factor variant fusion rotein, this albumen is composed as follows:
The segmental fusion rotein of bacterium thioredoxin and haFGF, wherein the haFGF fragment is that natural haFGF fragment or cysteine residues (as Cys16, Cys83, Cys117) partly or entirely sport the amino acid that can not cause that the fusion rotein space structure changes; Amino acid after the sudden change is Gly, Ser, Ala preferably, and most preferred is Ser, and the aminoacid sequence after the most preferred sudden change is seen sequence table 2.
The present invention also provides the preparation method of fusion rotein of the present invention, and this method may further comprise the steps:
A. the gene DNA segment of synthetic coding people aFGF aminoacid sequence, in this fragment, the cysteine residues of aFGF gene (cys) partly or entirely sports Gly, Ser, Ala, and most preferred is Ser;
B. the gene fragment that obtains among the step a. is inserted 3 ' end of bacterium thioredoxin (Tioredoxin) gene on the expression vector;
The expression vector recombinant plasmid dna that c. will contain the Tioredoxin-aFGF antigen-4 fusion protein gene transforms suitable intestinal bacteria; The preferred expression system of the present invention is an escherichia expression system, wherein preferred pET32a/BL21 (DE3); Also can select the pThioHisA/Top10 system;
D. this genetic engineering bacterium is prepared highly purified Tioredoxin-aFGF fusion rotein through fermentation, extraction, purification procedures;
E. the Tioredoxin-aFGF fusion rotein that purifying is obtained is prepared into stable liquid or freeze-dried preparation, for clinical use.
The dna sequence dna of Tioredoxin-aFGF fusion rotein of wherein encoding is seen sequence table 1
The aminoacid sequence of wherein most preferred Tioredoxin-aFGF fusion rotein is seen sequence table 2.
Be prepared into pharmaceutical composition with fusion rotein of the present invention as active constituents of medicine of the present invention also comprising, said composition can add some medicine acceptable carriers as required, can adopt the technology of pharmaceutics routine techniques to prepare said composition, composition of the present invention can be oral, also can parenteral administration, preferred compositions is that the injection form of unitary dose is as lyophilized injectable powder.Of the present inventionly in making medicine, be with a wide range of applications and vast market prospect.
Advantage of the present invention mainly shows:
1. recombinant human aFGF is very big to intestinal bacteria toxicity, therefore the expression in intestinal bacteria is very low, usually just can detect with Western blot, even also can only reach the expression amount (Jaye of 10mg/L after optimizing, M.Burgess, N, W.1987.J.Biol.Chem 262 (34): 16612-16617), we express in the fusion rotein mode and expression amount are reached account for whole bacterial protein more than 20%, and every liter of fermented liquid can obtain more than the pure product 200mg.
2. stability is higher than the aFGF of prototype aFGF and sudden change far away.37 ℃, 1 hour postprecipitation of prototype precipitates after more 4 hours fully, non-activity, and the Tioredoxin-aFGF fusion rotein has a little precipitation with this understanding after 4 hours, its specific activity is 1.2 * 10
5U/mg
Description of drawings:
Fig. 1: expression vector pET32a+ and multiple clone site structural representation thereof
Fig. 2: construction of recombinant plasmid operation chart:
Fig. 3: genetic engineering bacterium is induced back Tioredoxin-aFGF Expression of Fusion Protein electrophoretogram at IPTG
Fig. 4: the electrophoretogram of the Tioredoxin-aFGF fusion rotein behind the purifying
Embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
The structure of recombinant expressed human acid fibroblast growth factor variant antigen-4 fusion protein gene engineering bacteria
(1) the double-stranded DNA gene of synthetic coding people aFGF 1-140 amino-acid residue, and, introduce an Ala residue at prototype haFGF N-terminal in 5 ' end adding NcoI site, adding the SalI site at 3 ' end, sequence is as follows:
5’…catggctttcaacctgccgccgggtaactacaaaaaaccgaaactgctgtactcctccaacggtggtcac
ttcctgcgtatcctgccggacggtaccgttgacggtacccgtgaccgttccgaccagcacatccagctgcagctg
tccgctgaatccgttggtgaagtttacatcaaatccaccgaaaccggtcagtacctggctatggacaccgacggt
ctgctgtacggttcccagaccccgaacgaagaatccctgttcctggaacgtctggaagaaaaccactacaacacc
tacatctccaaaaaacacgctgaaaaaaactggttcgttggtctgaaaaaaaacggttcctccaaacgtggtccg
cgtacccactacggtcagaaagctatcctgttcctgccgctgccggtttcctccgactaagtcgac…3’
The gained dna fragmentation is cloned among the pUC18 with the NcoI/SalI site and preserves, called after pUC18aFGF.
(2) with the synthetic gene clone to suitable expression vector, its structure of preferred expression vector such as pET32a (buying from novagen biotech company) is seen accompanying drawing 1:
Host bacterium BL21 (DE3) is available from U.S. novagen company.
(3) structure, conversion, the enzyme of the structure of genetic engineering bacterium and screening expression plasmid are cut evaluation and are operated according to conventional molecular cloning, and the pET32aFGF expression plasmid is in the screening of escherichia coli expression and efficient expression engineering strain: (accompanying drawing 2)
To obtain transformant behind the expression plasmid pET32aFGF transformed into escherichia coli BL21 (DE3), picking list colony inoculation is in LB substratum (Amp
+100 μ g/mL), 37C, 220rpm, IPTG abduction delivering, SDS-PAGE electrophoresis detection.
There is the obvious expression band at the place at the 45000D molecular weight.(see figure 3)
The purifying of rh-aFGF variant fusion rotein
With the fermented liquid of fermentation culture gained, centrifugal (7000rpm 5min), collects thalline and (25mmol/L Tris, 0.15mol/L NaCl pH8.0) wash bacterium three times, remove the substratum residue with damping fluid through freezing large vol whizzer.
(1mmol/L EDTA pH8.0) suspends evenly, the ice bath cooling for 25mmol/L Tris, 0.15mol/LNaCl with damping fluid in 20% ratio (w/v) with the fermentation thalline of centrifugal collection.Regulate the operating pressure of APV 1000 refiners and break bacterium.
Thalline is after the high-pressure homogenization fragmentation, and (9000rpm 30min) obtains rough inclusion body to pass through high speed centrifugation again.Adopt " Guanidinium hydrochloride of 7mol/L, 50mmol/L Tris, pH8.0 " dissolving damping fluid as the rhaFGF inclusion body.The rhaFGF inclusion body suspends with above-mentioned damping fluid according to the ratio of weight in wet base in 1/5 (w/v), and stirring at room was dissolved about 12 hours, then through the centrifugal collection supernatant of 9000rpm, 30min.
With dilution method renaturation rhaFGF, renaturation buffer is: 25mmol/L Tris, 2mol/L urea, 0.15mol/LNaCl, lmmol/L EDTA, pH8.0.Renaturation 48 hours is carried out ultrafiltration and concentration then and (25mmol/LTris, 0.05mol/L NaCl pH8.0) dialyses to damping fluid.
Chelating Sepharose Fast Flow purifying Trx-aFGF:
Use the Chelating Sepharose Fast Flow of gel as Pharmacia, use 50mM Tris.Cl, pH8.0,0.5M NaCl damping fluid pre-equilibration pillar, not conjugated protein behind the last sample with the level pad wash-out, use 50mM Tris.Cl, pH8.0,1M NaCl washes foreign protein, uses 50mM Tris.Cl, pH8.0,50mM imidazoles wash-out purpose fusion rotein.The gained fusion rotein is replaced into 20mMPB with hyperfiltration process with damping fluid, pH7.2,0.4M NaCl.
Heparin affinitive layer purification Trx-aFGF
Use the Heparin Sepharose 6 Fast Flows of gel as Pharmacia, use 20mMPB, pH7.2,0.4MNaCl damping fluid pre-equilibration pillar, not conjugated protein behind the last sample with the level pad wash-out, use 20mMPB, pH7.2,0.6MNaCl washes foreign protein, uses 20mMPB, pH7.2,1M NaCl wash-out purpose fusion rotein.(accompanying drawing 4)
Secondly get the rhaFGF fusion rotein stoste of assay approval, at first adding human albumin to final concentration is 1%, with dilution buffer liquid A (25mmol/L Tris, 1% human albumin, pH8.0) electric conductivity value of rhaFGF fusion rotein stoste is diluted to 18.0mS/cm; Use then dilution buffer liquid B (25mmol/L Tris, 0.15mol/L NaCl, 1% human albumin, pH8.0) with the concentration dilution of rhaFGF fusion rotein in the sample to 0.2mg/ml, use the degerming of 0.22um membrane filtration at last, be rhaFGF fusion rotein work in-process.
1.0ml/ props up with the aseptic subpackaged one-tenth of the work in-process of assay approval, more than 8 hours, carries out freeze-drying through-40 ℃ of pre-freezes then, promptly gets freeze dried rhaFGF fusion rotein goods.
The liquid of Tioredoxin-aFGF fusion rotein and freeze-dried preparation
External application recombination human acidic mechanocyte cell growth factor (fusion rotein) freeze-dried preparation prescription is:
Tris 3.02mg
NaCl 9mg
Human albumin 10mg
Prop up freeze-drying after the packing by 1.0ml/, promptly every finished product contains 1 * 10
5IU (or 0.2mg) rhaFGF, 9mg NaCl, 3.02mg Tris and 10mg human albumin.
Embodiment 4
The physical and chemical property determining of Tioredox-aFGF
1. the mensuration of stoste purity
Measure by the HPLC method, chromatography column is TSK-GEL G2000SW (XL), and the result shows that its purity reaches more than 95%.
2. molecular weight determination
The molecular weight of measuring is 32968.49, and is consistent with theoretical guess value.
3. Determination of biological activity (mtt assay)
But fibroblast growth factor differential stimulus fibroblasts proliferation, differentiation, and it promotes fibroblast proliferation, differentiation, adopts Balb/c 3T3 cell strain, mtt assay to measure the biologic activity for preparing the rhaFGF fusion rotein in this research.Its specific activity 5 * 10
5U/mg.
4.rhaFGF terminal 15 determined amino acid sequences of fusion rotein N-, measurement result is consistent with expected results.
1 5 10 15
Ser-Asp-Lys-Ile-Ile-His-Leu-Thr-Asp-Asp-Ser-Phe-Asp-Thr-Asp
5.rhaFGF fusion rotein isoelectric point determination
Adopt leveling board PAGE electrophoretic method to detect.PI is 5.3
The study on the stability of rh-aFGF variant fusion rotein stoste and freeze-dried preparation
1. the stability of rh-aFGF variant fusion rotein stoste
This laboratory in 4 ℃, room temperature, 37 ℃, remakes determination of activity with the pure product separated deposit of aFGF of the aFGF of recombinant expressed prototype and amalgamation and expression.The result is as follows:
AFGF original shape and amalgamation and expression thermostability are relatively
Above result confirms to merge aFGF stability apparently higher than prototype aFGF.
2, the stability of rh-aFGF variant fusion rotein freeze-dried preparation
With freeze dried sample (specification: 1 * 10
5U/0.2mg) respectively in 2-8 ℃, room temperature and 37 ℃ of investigations that keep sample, and proportionately the relevant regulations in the product examine set pattern journey is examined the every quality index of sample.
(1) 2-8 ℃ of investigation that keeps sample: sample is placed 2-8 ℃ of refrigerator, be set in respectively and measure above index in March, June, September, December, 18 months, 24 months, 36 months etc.
(2) the room temperature investigation that keeps sample: sample is placed 25 ℃ of thermostat containers, be set in respectively and measure above index in March, June, September, December, 18 months, 24 months, 36 months etc.
(3) 37 ℃ of investigations that keep sample: sample is placed 37 ℃ of thermostat containers, be set in respectively January, February, March, etc. measure above index.
The result shows: 1, rh-aFGF (fusion rotein) lyophilized injectable powder has good stability when room temperature, 37 ℃ of preservations, deposits 3 months activity and does not see obvious decline.2, rh-aFGF (fusion rotein) lyophilized injectable powder is when low temperature (2-8 ℃) is preserved, and the investigation result that keeps sample showed that activity did not almost change in 18 months.
Embodiment 6
Rh-aFGF variant fusion rotein is used for trauma care
1, pharmacodynamic study
(1) the rhaFGF fusion rotein is to the effect of miniature pig wound repair
Adopt Beijing to produce under the miniature pig anesthesia and cause trauma model, rhaFGF with 30,60, three kinds of dosage of 90U/cm2 handle the surface of a wound, the next day, change dressings once, observed 14 days.The surface of a wound is taken pictures, transparent film is traced the weighing method record and hindered 4,8, the 14 days surface of a wound areas in back; Hinder the chamber volume with the water flood measurement; Normal dyeing after formalin fixed, primary part observation surface of a wound granulation tissue growth (comprising the capillary vessel growth, collagen deposition) changes with re-epithelialization, to estimate repairing effect.The result shows:
A, the surface of a wound area of handling through different treatment plans prolong with post burn and dwindle gradually, and rhaFGF 90U/cm2 dosage group result of treatment is more obvious.
B, the surface of a wound are hindered the chamber volume and prolonged with post burn and dwindle gradually, and be wherein more obvious with rhaFGF 90U/cm2 dosage group result of treatment.
As seen c, histological examination treat that to be sliced into fibroblast growth on the 8th day active, and quantity is many, and its capillary vessel plumule and inoblast quantity are significantly more than the blank group.Hindered back 14 days, the face of respectively forming all heals.
Can be drawn as drawing a conclusion by The above results: rhaFGF has the promotion repair to the miniature pig back knife wound surface of a wound.Show and promote the growth of surface of a wound granulation tissue, capillary vessel plumule to form and re-epithelialization.Show with 90U/cm2 dosage group and to promote that the wound repair effect is more obvious.
(2) the rhaFGF fusion rotein is to the repair of rabbit scald wound
Adopt Beijing to produce under the large ear rabbit anesthesia and cause dark II degree scald wound model, rhaFGF with 30,60, three kinds of dosage of 90U/cm2 handle the surface of a wound, the next day, change dressings once, observed 21 days.The surface of a wound is taken pictures, transparent film is traced the weighing method record and hindered 3,7,14, the 21 days surface of a wound areas in back; Wound was got wound tissue in 14,21 days, after 10% formalin fixed, and film-making, normal dyeing, the growth of primary part observation surface of a wound granulation tissue changes with re-epithelialization, to estimate repairing effect.The result shows:
A, respectively form the face area and prolong with post burn and dwindle gradually, rhaFGF 90U/cm2 dosage group result of treatment is more obvious.
B, histological examination section are dyeed through HE, as seen rhaFGF 90U/cm2 dosage group is hindered back 14 days major parts and is covered by newborn epidermis, surface attachment necrotic tissue in a small amount, and the surface of a wound heals substantially, the blank group lingering section surface of a wound, the necrotic tissue that surface attachment is more.Hindered back 21 days, the surface of a wound of rhaFGF treatment all heals, and epidermal area is thicker, the still residual a small amount of surface of a wound of blank group.
Can be drawn as drawing a conclusion by The above results: rhaFGF has the promotion repair to the rabbit back scald wound.Show and promote that surface of a wound granulation tissue is grown, necrotic tissue comes off and re-epithelialization.Show with 90U/cm2 dosage group and to promote that the wound repair effect is more obvious.
2, pharmacological toxicology research
(1) the wound and wound surface model experiment of Sprague-Dawley rat
Animal subject was used the scissors cropping at the back before 24 hours, the depilation area is about 40cm2, and polishing with emery paper in the depilation district blood point occurs to skin but do not have hemorrhage, this product evenly is coated on depilation district, animal subject back, and fixing with the gauze wrapping, after 24 hours, remove residue with asking to wash.By 14 days continuous observed and recorded, animal subject was active, the mental status, movable unusual for seeing; Breathe steadily, do not see cyanosis, tic; Appetite and stool no abnormality seen.Tangible irritant reaction is not seen in the administration part.Duration of test does not have animal dead.
(2) rabbit percutaneous drug delivery experiment repeatedly
40 of rabbit are divided 4 groups at random, and 10 every group, male and female half and half.Skin is smeared rhaFGF, and dosage is respectively 1000,3000,6000U/cm2 and control group (water for injection), and every day, percutaneous drug delivery was 1 time, and successive administration 28 days continues after the drug withdrawal to observe for 4 weeks.9 of the general physical signs of experimental observation, 10 of hematological indices, 15 of blood biochemicals, pathological examination kind of organ-tissue surplus 20.The result shows, compares with control group, and each administration treated animal fur fairing of duration of test, the mental status is good, behavioral activity is normal, breathes steadily, and feed is normal, that weight increase, administration local skin are not seen is coarse, chap, thicken, fash or focus of infection, and damaged skin is not seen cicatrization yet.Electrocardiogram(ECG, hematology, blood biochemical, organ weights and organ coefficient etc. all fluctuate in normal range, do not see that the regularity with toxicology meaning changes.During drug withdrawal and drug withdrawal 2 week the back animals do not produce rhaFGF antibody.Each internal organs of pathological examination are not seen the abnormal change relevant with medicine, and the administration local skin is organized the no abnormality seen hyperplasia.
(3) guinea pig skin hypersensitive test
Cavy cut off back wool with scissors in being tried in preceding 24 hours, and the every side of unhairing area is about 3 * 3cm2, got to be subjected to test product 0.2ml to be coated in depilation district, animal left side, and is fixing, continues 6 hours, and the 7th day and the 14th day in kind repeats once; Last is given and to be tried after the thing sensitization 14 days, will be tried thing 0.2ml and be coated in depilation district, animal right side, removes after 6 hours and is tried thing, observes immediately, and observes the national response situation of skin once more in 24,48,72 hours.The result shows that rhaFGF does not have sensitization, and the sensitization rate is 0.0%, does not see that erythema and oedema appear in guinea pig back administration district.
＜110〉Peng Juan Zhao Quan
＜120〉a kind of manufacturing of new fusion protein and application
<160>2
<210>1
<211>906
<212>DNA
＜213〉artificial sequence
<400>1
atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60
gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120
ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180
atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240
ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggycagttg 300
aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360
catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420
ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caaggccatg 480
gctttcaacc tgccgccggg taactacaaa aaaccgaaac tgctgtactc ctccaacggt 540
ggtcacttcc tgcgtatcct gccggacggt accgttgacg gtacccgtga ccgttccgac 600
cagcacatcc agctgcagct gtccgctgaa tccgttggtg aagtttacat caaatccacc 660
gaaaccggtc agtacctggc tatggacacc gacggtctgc tgtacggttc ccagaccccg 720
aacgaagaat ccctgttcct ggaacgtctg gaagaaaacc actacaacac ctacatctcc 780
aaaaaacacg ctgaaaaaaa ctggttcgtt ggtctgaaaa aaaacggttc ctccaaacgt 840
ggtccgcgta cccactacgg tcagaaagct atcctgttcc tgccgctgcc ggtttcctcc 900
<210>2
<211>301
<212>PRT
＜213〉artificial sequence
<400>2
Met?Ser?Asp?Lys?Ile?Ile?His?Leu?Thr?Asp?Asp?Ser?Phe?Asp?Thr
5 10 15
Asp?Val?Leu?Lys?Ala?Asp?Gly?Ala?Ile?Leu?Val?Asp?Phe?Trp?Ala
20 25 30
Glu?Trp?Cys?Gly?Pro?Cys?Lys?Met?Ile?Ala?Pro?Ile?Leu?Asp?Glu
35 40 45
Ile?Ala?Asp?Glu?Tyr?Gln?Gly?Lys?Leu?Thr?Val?Ala?Lys?Leu?Asn
50 55 60
Ile?Asp?Gln?Asn?Pro?Gly?Thr?Ala?Pro?Lys?Tyr?Gly?Ile?Arg?Gly
65 70 75
Ile?Pro?Thr?Leu?Leu?Leu?Phe?Lys?Asn?Gly?Glu?Val?Ala?Ala?Thr
80 85 90
Lys?Val?Gly?Ala?Leu?Ser?Lys?Gly?Gln?Leu?Lys?Glu?Phe?Leu?Asp
95 100 105
Ala?Asn?Leu?Ala?Gly?Ser?Gly?Ser?Gly?His?Met?His?His?His?His
110 115 120
His?His?Ser?Ser?Gly?Leu?Val?Pro?Arg?Gly?Ser?Gly?Met?Lys?Glu
125 130 135
Thr?Ala?Ala?Ala?Lys?Phe?Glu?Arg?Gln?His?Met?Asp?Ser?Pro?Asp
140 145 150
Leu?Gly?Thr?Asp?Asp?Asp?Asp?Lys?Ala?Met?Ala?Phe?Asn?Leu?Pro
155 160 165
Pro?Gly?Asn?Tyr?Lys?Lys?Pro?Lys?Leu?Leu?Tyr?Ser?Ser?Asn?Gly
170 175 180
Gly?His?Phe?Leu?Arg?Ile?Leu?Pro?Asp?Gly?Thr?Val?Asp?Gly?Thr
185 190 195
Arg?Asp?Arg?Ser?Asp?Gln?His?Ile?Gln?Leu?Gln?Leu?Ser?Ala?Glu
200 205 210
Ser?Val?Gly?Glu?Val?Tyr?Ile?Lys?Ser?Thr?Glu?Thr?Gly?Gln?Tyr
215 220 225
Leu?Ala?Met?Asp?Thr?Asp?Gly?Leu?Leu?Tyr?Gly?Ser?Gln?Thr?Pro
230 235 240
Asn?Glu?Glu?Ser?Leu?Phe?Leu?Glu?Arg?Leu?Glu?Glu?Asn?His?Tyr
245 250 255
Asn?Thr?Tyr?Ile?Ser?Lys?His?Ala?Glu?Glu?Lys?Asn?Trp?Phe?Val
260 265 270
Gly?Leu?Lys?Lys?Asn?Gly?Ser?Ser?Lys?Arg?Gly?Pro?Arg?Thr?His
275 280 285
Tyr?Gly?Gln?Lys?Ala?Ile?Leu?Phe?Leu?Pro?Leu?Pro?Val?Ser?Ser
290 295 300
Asp
301
Claims (10)
1. the fusion rotein of human acid fibroblast growth factor and Trx.
2. the fusion rotein of claim 1, wherein human acid fibroblast growth factor is natural human acid fibroblast growth factor or human acid fibroblast growth factor variant.
3. the fusion rotein of claim 2, wherein said human acid fibroblast growth factor variant are that natural haFGF fragment cysteine residues partly or entirely sports the amino acid that can not cause that the fusion rotein space structure changes.
4. the fusion rotein of claim 3, the wherein said amino acid that can not cause that the fusion rotein space structure changes is selected from Gly, Ser, Ala.
5. the fusion rotein of claim 4, haFGF variant part wherein be in its aminoacid sequence three Cys all by the variant of Ser alternate; Its fusion rotein aminoacid sequence is the sequence of sequence 2 in the sequence table.
6. the dna sequence dna of the fusion rotein of coding claim 1-5.
7. the dna sequence dna of claim 6 is sequences of sequence 1 in the sequence table.
8. the preparation method of the fusion rotein of claim 1 may further comprise the steps:
A. the gene DNA segment of synthetic coding people aFGF aminoacid sequence, in this fragment, the cysteine residues of aFGF gene (cys) partly or entirely sports Gly, Ser or Ala;
B. the gene fragment that obtains among the step a. is inserted 3 ' end of bacterium thioredoxin (Tioredoxin) gene on the expression vector;
The expression vector recombinant plasmid dna that c. will contain the Tioredoxin-aFGF antigen-4 fusion protein gene transforms suitable intestinal bacteria; This genetic engineering bacterium is prepared highly purified Tioredoxin-aFGF fusion rotein through fermentation, extraction, purification procedures.
9. the preparation method of claim 8, wherein Shi Yi intestinal bacteria are pET32a.
10. the preparation method of claim 8 is wherein fermented, extraction, purification procedures be: genetic engineering bacterium is seeded in the suitable culture base cultivates, the zymophyte of centrifugal collection; Thalline obtains rough inclusion body through high speed centrifugation again after the high-pressure homogenization fragmentation; Dissolved inclusion body 12 hours with the Guanidinium hydrochloride damping fluid that contains 7mol/L, the heart is collected supernatant then; With dilution method renaturation rhaFGF, renaturation 48 hours carries out ultrafiltration and concentration and damping fluid is dialysed removing Guanidinium hydrochloride then; Purifying at first adopts the affine exchange column chromatography purification of Chelating Sepharose Fast Flow Trx-aFGF, with the buffer solution elution purpose fusion rotein that contains imidazoles; Use Heparin Sepharose 6Fast Flow affinitive layer purification Tioredoxin-aFGF fusion rotein at last, with containing 1M NaCl wash-out purpose fusion rotein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100854972A CN100334114C (en) | 2005-07-22 | 2005-07-22 | Novel fusion protein production and uses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100854972A CN100334114C (en) | 2005-07-22 | 2005-07-22 | Novel fusion protein production and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1769299A true CN1769299A (en) | 2006-05-10 |
| CN100334114C CN100334114C (en) | 2007-08-29 |
Family
ID=36750865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100854972A Expired - Fee Related CN100334114C (en) | 2005-07-22 | 2005-07-22 | Novel fusion protein production and uses |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100334114C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2528251C2 (en) * | 2012-12-07 | 2014-09-10 | Общество с ограниченной ответственностью "Гематологическая Корпорация" (ООО "ГемаКор") | FUSED PROTEIN OF THIOREDOXIN AND INFESTIN 4 DOMAIN, METHOD FOR PREPARING IT, EXPRESSION PLASMID DNA CODING FUSED PROTEIN, AND BACTERIUM Escherichia coli TRANSFORMED BY THIS PLASMID DNA |
| CN107961394A (en) * | 2017-10-27 | 2018-04-27 | 南开大学 | Anti- HPV uterine neck protective dressing design based on ternary fusion protein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1232532C (en) * | 1996-12-27 | 2005-12-21 | 暨南大学生物工程研究所 | Fibroblast growth factor-2 analogue, producing process and application thereof |
| CN1504573A (en) * | 2003-09-01 | 2004-06-16 | 广州暨南大学医药生物技术研究开发中 | Confluent protein capable of self-cracking into polypeptide with antibiosis and reparation function |
-
2005
- 2005-07-22 CN CNB2005100854972A patent/CN100334114C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2528251C2 (en) * | 2012-12-07 | 2014-09-10 | Общество с ограниченной ответственностью "Гематологическая Корпорация" (ООО "ГемаКор") | FUSED PROTEIN OF THIOREDOXIN AND INFESTIN 4 DOMAIN, METHOD FOR PREPARING IT, EXPRESSION PLASMID DNA CODING FUSED PROTEIN, AND BACTERIUM Escherichia coli TRANSFORMED BY THIS PLASMID DNA |
| CN107961394A (en) * | 2017-10-27 | 2018-04-27 | 南开大学 | Anti- HPV uterine neck protective dressing design based on ternary fusion protein |
| CN107961394B (en) * | 2017-10-27 | 2020-10-13 | 南开大学 | anti-HPV cervical wound-protecting dressing design based on ternary fusion protein |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100334114C (en) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1304450A (en) | Novel insulin analogs with enhanced zinc binding | |
| CN1178950C (en) | Corpuscles of stannius protein, stanniocalcin | |
| CN101041693A (en) | Novel blood sugar lowing polypeptide and uses thereof | |
| CN1653177A (en) | Muteins of placental growth factor type 1, preparation method and application thereof | |
| CN1769299A (en) | Novel fusion protein production and uses | |
| CN1160721A (en) | Fibrillating cell growth factor-2 analogue and its production method and use | |
| CN1561960A (en) | Method for preparing biological beauty skin-care product containing keratin cell growth factor-2 and recombined human keratin cell growth factor-2 | |
| CN1232532C (en) | Fibroblast growth factor-2 analogue, producing process and application thereof | |
| CN1310949C (en) | Bifunctional chimeric profein possessing inhibiting leucocyte function and thrombin activity | |
| CN1746188A (en) | Analog of GLP-1 | |
| CN1082091C (en) | Recombination human tumour necrofactor and preparation method | |
| CN1247616C (en) | New monomeric insulin and its medicinal composition and prepn process | |
| CN1919870A (en) | Cat alpha interferon, encode gene and application thereof | |
| CN1690078A (en) | A highly biologically active keratinocyte growth factor mutant, its preparation method and use | |
| CN1277259A (en) | Homologous protein of late embryo ample-protein and its code sequence | |
| CN1057119C (en) | Reformed human tumor necrosin derivative and preparation method thereof | |
| CN1754886A (en) | Blood platelet reinforcing protein and application thereof | |
| CN1237173C (en) | Hemolytic peptide precursor gene of Asian-African wasp aptoxin, polypeptide coded by it and its preparing process | |
| CN1580261A (en) | CC10 protein preparation and use | |
| CN1500809A (en) | Fibroblast growth factor-2 analogue, producing process and application thereof | |
| CN1290747A (en) | New human metal thioalbumen and its coding sequence | |
| CN1784420A (en) | Method for the production of an N-terminally modified chemotactic factor | |
| CN1107891A (en) | Human megacaryocyte auxin and its separating purification and gene clone method and application | |
| CN1297930A (en) | Human thrombus protein 30 as one new kind of polypeptide and polynucleotides encoding this polypeptide | |
| CN1394958A (en) | Recombinant glucokinase (126) and its gene efficient expression engineering strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XIZHANG TIANXING BIOLOGICAL PHARMACEUTICAL CO., L Free format text: FORMER OWNER: PENG JUAN ADDRESS Effective date: 20081121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081121 Address after: Lhasa City, Tibet autonomous region Jinzhu West Road No. 158 zip code: 850000 Patentee after: Tianjin Bofa Biotechnology Co., Ltd. Address before: Room 37, room 651, Lane 401, Nu River Road, Shanghai, China: 200333 Co-patentee before: Zhao Quan Patentee before: Peng Jun |
|
| ASS | Succession or assignment of patent right |
Owner name: XIZHANG TIANXING BIOLOGICAL PHARMACEUTICAL CO., LT Free format text: FORMER OWNER: PENG JUAN Effective date: 20081121 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Tianjin Bofa Biotechnology Co., Ltd. Assignor: Chengdu Bofa Biotechnology Co., Ltd. Contract record no.: 2010510000099 Denomination of invention: Novel fusion protein production and uses Granted publication date: 20070829 License type: Exclusive License Open date: 20060510 Record date: 20101026 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Chengdu Bofa Biotechnology Co., Ltd. Assignor: Tianjin Bofa Biotechnology Co., Ltd. Contract record no.: 2010510000099 Denomination of invention: Novel fusion protein production and uses Granted publication date: 20070829 License type: Exclusive License Open date: 20060510 Record date: 20101026 |
|
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN BOFA BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: TIBET TIANXING BIOPHARMACEUTICAL CO., LTD. Effective date: 20110317 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 850000 NO. 158, JINZHU WEST ROAD, LASA CITY, TIBET AUTONOMOUS REGION TO: 300457 ROOM S1001, LABORATORY BUILDING, TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE, NO. 220, DONGTING ROAD, TIANJIN ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110317 Address after: 300457 No. 220, Dongting Road, Tianjin economic and Technological Development Zone, S1001 laboratory, Tianjin International Joint Research Institute of biomedicine Patentee after: Xizang Tianxing Biomedical Co., Ltd. Address before: Lhasa City Jinzhu West Road No. 158 850000 Tibet Autonomous Region Patentee before: Tianjin Bofa Biotechnology Co., Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: Xizang Tianxing Biomedical Co., Ltd. Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070829 Termination date: 20190722 |